Pfizer’s Xeljanz Approved in EU for Adults with Moderate to Severe Ulcerative Colitis

Pfizer’s Xeljanz Approved in EU for Adults with Moderate to Severe Ulcerative Colitis
The European Commission has approved Pfizer‘s Xeljanz (tofacitinib) for the treatment of adults with moderate to severe active ulcerative colitis (UC) who have failed to fully respond to other therapies. The approved regimen is 10 mg of oral Xeljanz twice a day for at least eight weeks, after which patients can continue on the twice-daily therapy, either

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *